Effects of Levosimendan Pretreatment in Patients With Low Ejection Fraction (40 % or Less) Undergoing CABG: a Randomised, Double Blind, Multicenter Trial

Trial Profile

Effects of Levosimendan Pretreatment in Patients With Low Ejection Fraction (40 % or Less) Undergoing CABG: a Randomised, Double Blind, Multicenter Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Low cardiac output
  • Focus Therapeutic Use
  • Acronyms LICORN
  • Most Recent Events

    • 08 Aug 2017 Primary endpoint (Confirmed low cardiac output syndrome) has not been met, as per results published in the JAMA: the Journal of the American Medical Association.
    • 08 Aug 2017 Results published in the JAMA: the Journal of the American Medical Association
    • 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top